Samsung Biologics (Korea) Investor Sentiment

207940 Stock   934,000  2,000  0.21%   
About 55% of Samsung Biologics' investor base is interested to short. The analysis of current outlook of investing in Samsung Biologics Co suggests that many traders are impartial regarding Samsung Biologics' prospects. The current market sentiment, together with Samsung Biologics' historical and current headlines, can help investors time the market. In addition, many technical investors use Samsung Biologics stock news signals to limit their universe of possible portfolio assets.
  
over six months ago at news.google.com         
Foreign investors have changed. Foreigners, who bought a net 413.6 billion won a day on the KOSPI on...
Google News at Macroaxis
over six months ago at news.google.com         
Investing in Samsung BiologicsLtd five years ago would have delivered you a 161 percent gain - Simpl...
Google News at Macroaxis
over six months ago at news.google.com         
Recently, as the KOSPI has repeatedly fluctuated, emperor stocks, whose price per share once excee.....
Google News at Macroaxis
over six months ago at news.google.com         
Samsung Biologics Reports First Quarter 2024 Financial Results - Morningstar
Google News at Macroaxis
over six months ago at news.google.com         
Samsung Bioepis, Celltrion make biosimilar inroads in Europe, US - BioWorld Online
Google News at Macroaxis
over six months ago at news.google.com         
Samsung BioLogics says decision pending on making Moderna vaccine as report ignites share - Yahoo Mo...
Google News at Macroaxis
over six months ago at news.google.com         
What Samsung Biologics Co.,Ltd.s PE Is Not Telling You - Simply Wall St
Google News at Macroaxis
over six months ago at news.google.com         
Samsung Biologics Co.,Ltd.s Stock Has Seen Strong Momentum Does That Call For Deeper Study Of Its Fi...
Google News at Macroaxis
over six months ago at news.google.com         
Samsung Biologics Co.,Ltd.s Stock Has Seen Strong Momentum Does That Call For Deeper Study Of ... - ...
Google News at Macroaxis
over six months ago at news.google.com         
Why Are Shareholders Upset with LG Energy Solution, Samsung Biologics - BusinessKorea
Google News at Macroaxis
over six months ago at news.google.com         
We pay dividends to Kosdaq even for small-cap stocks with a market capitalization of tens of billio....
Google News at Macroaxis
over six months ago at news.google.com         
Key Samsung Shareholder Vote to Test Koreas Commitment to Corporate Reforms - Yahoo Canada Finance
Google News at Macroaxis
over six months ago at news.google.com         
South Korean Shares Close Higher After US Fed Chief Hints at Rate Cuts Samsung Biologics Adds 1 perc...
Google News at Macroaxis
over six months ago at news.google.com         
Samsung BiologicsLtd Full Year 2023 Earnings EPS 12,051 - Simply Wall St
Google News at Macroaxis
over six months ago at news.google.com         
Public companies who have a significant stake must be disappointed along with institutions after Sam...
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Samsung Biologics that are available to investors today. That information is available publicly through Samsung media outlets and privately through word of mouth or via Samsung internal channels. However, regardless of the origin, that massive amount of Samsung data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Samsung Biologics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Samsung Biologics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Samsung Biologics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Samsung Biologics alpha.

Samsung Biologics Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for Samsung Stock analysis

When running Samsung Biologics' price analysis, check to measure Samsung Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Samsung Biologics is operating at the current time. Most of Samsung Biologics' value examination focuses on studying past and present price action to predict the probability of Samsung Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Samsung Biologics' price. Additionally, you may evaluate how the addition of Samsung Biologics to your portfolios can decrease your overall portfolio volatility.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios